Check out these 7 abstracts powered by COTA’s RWD
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study.
Racial and ethnic representation in large B-cell lymphoma trials and real-world databases.
Real-world outcomes with novel therapies in R/R DLBCL.
An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).
Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
Interested in learning more about how we can transform cancer care together?
